CoChat

Adjuvant Transarterial Chemoembolization for HBV-Related Hepatocellular Carcinoma After Resection: A Randomized Controlled Study

Wang, Zheng, Ren, Zhenggang, Chen, Yi, Hu, Jie, Yang, Guohuan, Yu, Lei, Yang, Xinrong, Huang, Ao, Zhang, Xin, Zhou, Shaolai, Sun, Huichuan, Wang, Yanhong, Ge, Ningling, Xu, Xiaoyu, Tang, Zhaoyou, Lau, Wanyee, Fan, Jia, Wang, Jiping, Zhou, Jian · 2018 · Clinical Cancer Research

Published version of a preprint

The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.

Abstract

Purpose: The survival of patients with hepatocellular carcinoma (HCC) recurrence after curative resection is usually poor. We sought to evaluate the safety and efficacy of adjuvant transarterial chemoembolization (TACE) in HBV-related HCC patients with an intermediate (a single tumor larger than 5 cm without microvascular invasion) or high risk (a single tumor with microvascular invasion, or two or three tumors) of recurrence. Experimental Design: In this randomized phase 3 trial, 280 eligible patients were assigned to adjuvant TACE (n = 140) or no adjuvant treatment (control; n = 140) groups. The primary endpoint was recurrence-free survival (RFS); secondary endpoints included overall survival (OS) and safety. Multivariable Cox-proportional hazards model was used to determine the independent impact of TACE on patients' outcomes. Results: Patients who received adjuvant TACE had a significantly longer RFS than those in the control group [56.0% vs. 42.1%, P = 0.01; HR, 0.68; 95% confidence interval (CI), 0.49–0.93]. Patients in the adjuvant TACE group had 7.8% higher 3-year OS rate than the control group (85.2% vs. 77.4%; P = 0.04; HR, 0.59; 95% CI, 0.36–0.97). The impact of adjuvant TACE on RFS and OS remained significant after controlling for other known prognostic factors (HR, 0.67; P = 0.01 for RFS; and HR, 0.59; P = 0.04 for OS). There was no grade 3 or 4 toxicity after adjuvant TACE. Conclusions: For patients with HBV-related HCC who had an intermediate or high risk of recurrence after curative hepatectomy, our study showed adjuvant TACE significantly reduced tumor recurrence, improved RFS and OS, and the procedure was well tolerated. Clin Cancer Res; 24(9); 2074–81. ©2018 AACR.

Overview

Integrity signals

Registry

Crossref · 10.1158/1078-0432.ccr-17-2899

Cites

30 of 30 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 30 references

Cited by

See all 331

Metadata

Authors
Wang, Z., Ren, Z., Chen, Y., Hu, J., Yang, G., Yu, L., Yang, X., Huang, A., Zhang, X., Zhou, S., Sun, H., Wang, Y., Ge, N., Xu, X., Tang, Z., Lau, W., Fan, J., Wang, J., & Zhou, J.
Affiliations
  • Fudan University (CN)
  • 1Liver Cancer Institute, Zhongshan Hospital, Fudan University; Key Laboratory of Carcinogenesis and Cancer Invasion, Ministry of Education, Fudan University, Shanghai, China.
  • Chinese University of Hong Kong (HK)
  • Brigham and Women's Hospital (US)
Venue
Clinical Cancer Research
Published
2018-04-30
Volume
24
Issue
9
Pages
2074-2081
ISSN
  • 1078-0432 (ISSN-L)
  • 1557-3265
OpenAlex
W2787942673
Cited by
318
References
30
Citations by year
2026: 23 · 2025: 46 · 2024: 43 · 2023: 66 · 2022: 37 · 2021: 53 · 2020: 27 · 2019: 17 · 2018: 6
FWCI
16.44
Type
journal article
Language
en
Open access
closed
Locations
  • Clinical Cancer Research (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • National Science and Technology Major Project (2018ZX10723204)
  • National Key R&D Program of China (2016YFC0902400)
  • National Natural Science Foundation of China (81772578)
Topics
  • Health Sciences › Medicine › Hepatology › Hepatocellular Carcinoma Treatment and Prognosis
  • Health Sciences › Medicine › Epidemiology › Hepatitis B Virus Studies
  • Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
Keywords
hepatocellular carcinoma, HBV-related liver cancer, hepatectomy, tumor recurrence, recurrence-free survival, overall survival, microvascular invasion
MeSH terms
Adult, Aged, Antineoplastic Combined Chemotherapy Protocols, Female, Hepatitis B, Hepatitis B virus, Carcinoma, Hepatocellular, Humans, Liver Neoplasms, Male, Middle Aged, Chemoembolization, Therapeutic, Treatment Outcome, Kaplan-Meier Estimate, Young Adult, Chemoradiotherapy, Adjuvant

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Adjuvant Transarterial Chemoembolization for HBV-Related Hepatocellular Carcinoma After Resection: A Randomized Controlled Study. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-17-2899
The paper
Wang, Z., Ren, Z., Chen, Y., Hu, J., Yang, G., Yu, L., Yang, X., Huang, A., Zhang, X., Zhou, S., Sun, H., Wang, Y., Ge, N., Xu, X., Tang, Z., Lau, W., Fan, J., Wang, J., & Zhou, J. (2018). Adjuvant Transarterial Chemoembolization for HBV-Related Hepatocellular Carcinoma After Resection: A Randomized Controlled Study. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-17-2899

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.